title: Is day +1 omission of methotrexate associated with higher incidence of acute GvHD in hematopoietic stem cell transplantation?
authors.affiliation: Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
authors.forename: E
authors.initials: E
authors.lastname: Leon-Rodriguez
authors.affiliation: Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
authors.forename: M M
authors.initials: MM
authors.lastname: Rivera-Franco
authors.affiliation: Department of Hematology and Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
authors.forename: A
authors.initials: A
authors.lastname: Campos-Castro
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D064591:Allografts; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D015996:Survival Rate; D013997:Time Factors
chemical_list: D008727:Methotrexate